Advertisement

Osteoporosis International

, Volume 17, Issue 9, pp 1410–1419 | Cite as

The effect of cyclooxygenase-2 inhibitors on bone mineral density: results from the Canadian Multicentre Osteoporosis Study

  • J. B. Richards
  • L. Joseph
  • K. Schwartzman
  • N. Kreiger
  • A. Tenenhouse
  • D. Goltzman
  • For the Canadian Multicentre Osteoporosis Study (CaMos)
Original Article

Abstract

Introduction

The use of cyclooxygenase-2 (COX-2) inhibitors has been demonstrated to not only impair load-induced bone formation but also prevent menopause-associated bone loss. We hypothesized that COX-2 inhibitor use would be associated with increased bone mineral density (BMD) in postmenopausal women not using estrogen therapy and, conversely, with decreased BMD in men.

Methods

The Canadian Multicentre Osteoporosis Study is a longitudinal, randomly selected, population-based community cohort. We present data from men (n=2,004) and postmenopausal women age 65 and older (n=2,776) who underwent a BMD measurement and structured interview in the 5th year of the study. The outcome measure was percent difference in BMD (g/cm2).

Results

Daily COX-2 inhibitor use was reported by 394 subjects. In men, daily use of COX-2 inhibitors was associated with a lower BMD at all hip sites, with a percent difference of −3.1% [95% confidence interval (CI), −6.0, −0.3] between users and nonusers at total hip. In postmenopausal women not using estrogen replacement therapy, daily COX-2 inhibitor use was associated with higher BMD at most sites [percent difference at total hip: +3.0% (95% CI, 0.3, 5.8)]. These effects appeared to be dose-dependent.

Conclusion

COX-2 inhibitor use was associated with a lower BMD in men and, on the other hand, with a higher BMD in postmenopausal women not using estrogen replacement therapy. Men who have used COX-2 inhibitors may wish to seek BMD measurement to assess their fracture risk. However, COX-2 inhibitors may have utility in postmenopausal women if bone-selective analogs can be developed.

Keywords

Bone mineral density Cyclooxygenase-2 inhibitors Inflammation Osteoporosis 

Notes

Acknowledgements

The authors wish to acknowledge the assistance of Claudie Berger and Cristine Leroux with data management and the assistance of Dr. Suzanne Morin with data analysis.

Investigators for the CaMos Study Group:

CaMos Coordinating Centre, McGill University, Montreal, Quebec: David Goltzman (co-principal investigator), Nancy Kreiger (co-principal investigator), Alan Tenenhouse (senior researcher), Suzette Poliquin (national coordinator), Suzanne Godmaire (research assistant), Claudie Berger (study statistician), Lawrence Joseph (former study statistician).

Memorial University, St. John’s Newfoundland: Carol Joyce (director), Emma Sheppard (coordinator).

Dalhousie University, Halifax, Nova Scotia: Susan Kirkland, Stephanie Kaiser (codirectors), Barbara Stanfield (coordinator).

Laval University, Quebec City, Quebec: Jacques P. Brown (director), Louis Bessette (co-director), Evelyne Lejeune (coordinator), Marc Gendreau (Imaging Coordinator).

Queen’s University, Kingston, Ontario: Tassos Anastassiades (director), Tanveer Towheed (co-director), Barbara Matthews (coordinator).

University of Toronto, Toronto, Ontario: Bob Josse (director), Tim Murray (co-director), Barbara Gardner-Bray (coordinator).

McMaster University, Hamilton, Ontario: Jonathan D. Adachi (director), Alexandra Papaioannou (co-director), Laura Pickard (coordinator).

University of Saskatchewan, Saskatoon, Saskatchewan: Wojciech P. Olszynski (director), Jola Thingvold (coordinator).

University of Calgary, Calgary, Alberta: David A. Hanley (director), Jane Allan (coordinator).

University of British Columbia, Vancouver, British Columbia: Jerilynn C. Prior (director), Yvette Vigna (coordinator).

References

  1. 1.
    Raisz LG (1999) Prostaglandins and bone: physiology and pathophysiology. Osteoarthr Cartil 7(4):419–421PubMedCrossRefGoogle Scholar
  2. 2.
    Pfeilschifter J, Koditz R, Pfohl M, Schatz H (2002) Changes in proinflammatory cytokine activity after menopause. Endocr Rev 23(1):90–119PubMedCrossRefGoogle Scholar
  3. 3.
    Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, Konstam MA, Baron JA, the Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators (2005) Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352(11):1092–1102PubMedCrossRefGoogle Scholar
  4. 4.
    Solomon SD, McMurray JJV, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M, the Adenoma Prevention with Celecoxib (APC) Study Investigators (2005) Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352(11):1071–1080PubMedCrossRefGoogle Scholar
  5. 5.
    Thorsen K, Kristoffersson AO, Lerner UH, Lorentzon RP (1996) In situ microdialysis in bone tissue. Stimulation of prostaglandin E(2) release by weight-bearing mechanical loading. J Clin Invest 98(11):2446–2449PubMedCrossRefGoogle Scholar
  6. 6.
    Zaman G, Suswillo RFL, Cheng MZ, Tavares IA, Lanyon LE (1997) Early responses to dynamic strain change and prostaglandins in bone-derived cells in culture. J Bone Miner Res 12(5):769–777PubMedCrossRefGoogle Scholar
  7. 7.
    Bakker AD, Klein-Nulend J, Burger EH (2003) Mechanotransduction in bone cells proceeds via activation of COX-2, but not COX-1. Biochem Biophys Res Commun 305(3):677–683PubMedCrossRefGoogle Scholar
  8. 8.
    Klein-Nulend J, Burger EH, Semeins CM, Raisz LG, Pilbeam CC (1997) Pulsating fluid flow stimulates prostaglandin release and inducible prostaglandin G/H synthase mRNA expression in primary mouse bone cells. J Bone Miner Res 12(1):45–51PubMedCrossRefGoogle Scholar
  9. 9.
    Forwood MR (1996) Inducible cyclo-oxygenase (COX-2) mediates the induction of bone formation by mechanical loading in vivo. J Bone Miner Res 11(11):1688–1693PubMedGoogle Scholar
  10. 10.
    Okada Y, Lorenzo JA, Freeman AM, Tomita M, Morham SG, Raisz LG, Pilbeam CC (2000) Prostaglandin G/H synthase-2 is required for maximal formation of osteoclast-like cells in culture. J Clin Invest 105(6):823–832PubMedCrossRefGoogle Scholar
  11. 11.
    Min YK, Rao Y, Okada Y, Raisz LG, Pilbeam CC (1998) Regulation of prostaglandin G/H synthase-2 expression by interleukin-1 in human osteoblast-like cells. J Bone Miner Res 13(7):1066–1075PubMedCrossRefGoogle Scholar
  12. 12.
    Kawaguchi H, Pilbeam CC, Vargas SJ, Morse EE, Lorenzo JA, Raisz LG (1995) Ovariectomy enhances and estrogen replacement inhibits the activity of bone-marrow factors that stimulate prostaglandin production in cultured mouse calvariae. J Clin Invest 96(1):539–548PubMedCrossRefGoogle Scholar
  13. 13.
    Hardy MM, Seibert K, Manning PT, Currie MG, Woerner BM, Edwards D, Koki A, Tripp CS (2002) Cyclooxygenase 2-dependent prostaglandin E-2 modulates cartilage proteoglycan degradation in human osteoarthritis explants. Arthritis Rheum 46(7):1789–1803PubMedCrossRefGoogle Scholar
  14. 14.
    Cenci S, Weitzmann MN, Roggia C, Namba N, Novack D, Woodring J, Pacifici R (2000) Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-alpha. J Clin Invest 106(10):1229–1237PubMedCrossRefGoogle Scholar
  15. 15.
    Hofbauer LC, Lacey DL, Dunstan CR, Spelsberg TC, Riggs BL, Khosla S (1999) Interleukin-1 beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone 25(3):255–259PubMedCrossRefGoogle Scholar
  16. 16.
    Bauer DC, Orwoll ES, Fox KM, Vogt TM, Lane NE, Hochberg MC, Stone K, Nevitt MC (1996) Aspirin and NSAID use in older women: effect on bone mineral density and fracture risk. J Bone Miner Res 11(1):29–35PubMedGoogle Scholar
  17. 17.
    Morton DJ, Barrett-Connor EL, Schneider DL (1998) Nonsteroidal anti-inflammatory drugs and bone mineral density in older women: the Rancho Bernardo study. J Bone Miner Res 13(12):1924–1931PubMedCrossRefGoogle Scholar
  18. 18.
    Carbone LD, Tylavsky FA, Cauley JA, Harris TB, Lang TF, Bauer DC, Barrow KD, Kritchevsky SB (2003) Association between bone mineral density and the use of nonsteroidal anti-inflammatory drugs and aspirin: impact of cyclooxygenase selectivity. J Bone Miner Res 18(10):1795–1802PubMedCrossRefGoogle Scholar
  19. 19.
    Lane NE, Bauer DC, Nevitt MC, Pressman AR, Cummings SR (1997) Aspirin and nonsteroidal antiinflammatory drug use in elderly women: effects on a marker of bone resorption. J Rheumatol 24(6):1132–1136PubMedGoogle Scholar
  20. 20.
    Vane JR, Botting RM (2003) The mechanism of action of aspirin. Thromb Res 110(5–6):255–258PubMedCrossRefGoogle Scholar
  21. 21.
    Kreiger N, Tenenhouse A, Joseph L, Mackenzie T, Poliquin S, Brown JP, Prior JC, Rittmaster RS (1999) Research notes: the Canadian Multicentre Ssteoporosis Study (CaMos): background, rationale, methods. Can J Aging 18(3):376–387Google Scholar
  22. 22.
    Geba GP, Weaver AL, Polis AB, Dixon ME, Schnitzer TJ, for the VACT Group (2002) Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee: a randomized trial. JAMA 287(1):64–71PubMedCrossRefGoogle Scholar
  23. 23.
    Genant HK, Grampp S, Gluer CC, Faulkner KG, Jergas M, Engelke K, Hagiwara S, Vankuijk C (1994) Universal standardization for dual X-ray absorptiometry—patient and phantom cross-calibration results. J Bone Miner Res 9(10):1503–1514PubMedCrossRefGoogle Scholar
  24. 24.
    Pearson J, Dequeker J, Henley M, Bright J, Reeve J, Kalender W, Lavaljeantet AM, Ruegsegger P, Felsenberg D, Adams J, Birkenhager JC, Braillon P, Curiel MD, Fischer M, Galan F, Geusens P, Hyldstrup L, Jaeger P, Jonson R, Kalefezras J, Kotzki P, Kroger H, Vanlingen A, Nilsson S, Osteaux M, Cano RP, Reid DM, Reiners C, Ribot C, Schneider P, Slosman DO, Wittenberg G (1995) European semi-anthropomorphic spine phantom for the calibration of bone densitometers: assessment of precision, stability and accuracy. The European Quantitation of Osteoporosis Study Group. Osteoporos Int 5(3):174–184PubMedCrossRefGoogle Scholar
  25. 25.
    Jamal SA, Browner WS, Bauer DC, Cummings SR (1998) Intermittent use of nitrates increases bone mineral density: the study of osteoporotic fractures. J Bone Miner Res 13(11):1755–1759PubMedCrossRefGoogle Scholar
  26. 26.
    Cryer B, Feldman M (1998) Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med 104(5):413–421PubMedCrossRefGoogle Scholar
  27. 27.
    Shumaker SA, Legault C, Kuller L, Rapp SR, Thal L, Lane DS, Fillit H, Stefanick ML, Hendrix SL, Lewis CE, Masaki K, Coker LH, for the Women’s Health Initiative Memory Study (2004) Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: women’s health initiative memory study. JAMA 291(24):2947–2958PubMedCrossRefGoogle Scholar
  28. 28.
    Writing Group for the Women’s Health Initiative Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women’s health initiative randomized controlled trial. JAMA 288(3):321–333CrossRefGoogle Scholar
  29. 29.
    Brunner RL, Gass M, Aragaki A, Hays J, Granek I, Woods N, Mason E, Brzyski R, Ockene J, Assaf A, LaCroix A, Matthews K, Wallace R, for the Women’s Health Initiative Investigators (2005) Effects of conjugated equine estrogen on health-related quality of life in postmenopausal women with hysterectomy: results from the women’s health initiative randomized clinical trial. Arch Intern Med 165(17):1976–1986PubMedCrossRefGoogle Scholar
  30. 30.
    Roth GJ, Stanford N, Majerus PW (1975) Acetylation of prostaglandin synthase by aspirin. Proc Natl Acad Sci U S A 72(8):3073–3076PubMedCrossRefGoogle Scholar
  31. 31.
    Stewart A, Black AJ (2000) Bone mineral density in osteoarthritis. Curr Opin Rheumatol 12(5):464–467PubMedCrossRefGoogle Scholar
  32. 32.
    Hochberg MC, Altman RD, Brandt KD, Clark BM, Dieppe PA, Griffin MR, Moskowitz RW, Schnitzer TJ (1995) Guidelines for the medical-management of osteoarthritis. 1. Osteoarthritis of the hip. Arthritis Rheum 38(11):1535–1540PubMedCrossRefGoogle Scholar
  33. 33.
    Bertin P, Keddad K, Jolivet-Landreau I (2004) Acetaminophen as symptomatic treatment of pain from osteoarthritis. Joint Bone Spine 71(4):266–274PubMedCrossRefGoogle Scholar
  34. 34.
    Cauley JA, Fullman RL, Stone KL, Zmuda JM, Bauer DC, Barrett-Connor E, Ensrud K, Lau EM, Orwoll ES (2005) Factors associated with the lumbar spine and proximal femur bone mineral density in older men. Osteoporos Int 16(12):1525–1537PubMedCrossRefGoogle Scholar
  35. 35.
    Meunier PJ, Slosman DO, Delmas PD, Sebert JL, Brandi ML, Albanese C, Lorenc R, Pors-Nielsen S, De Vernejoul MC, Roces A, Reginster JY (2002) Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis—a 2-year randomized placebo controlled trial. J Clin Endocrinol Metab 87(5):2060–2066PubMedCrossRefGoogle Scholar
  36. 36.
    Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW, Dequeker J, Favus M, Seeman E, Recker RR, Capizzi T, Santora AC, Lombardi A, Shah RV, Hirsch LJ, Karpf DB, The Alendronate Phase III Osteoporosis Treatment Study Group (1995) Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 333(22):1437–1444PubMedCrossRefGoogle Scholar
  37. 37.
    Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH III, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD, for the Vertebral Efficacy with Risedronate Therapy Study Group (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA 282(14):1344–1352PubMedCrossRefGoogle Scholar
  38. 38.
    Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR, for the Multiple Outcomes of Raloxifene Evaluation Investigators (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 282(7):637–645PubMedCrossRefGoogle Scholar
  39. 39.
    Cummings SR (1993) Bone density at various sites for prediction of hip fractures. Lancet 341:72–75PubMedCrossRefGoogle Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2006

Authors and Affiliations

  • J. B. Richards
    • 1
    • 2
  • L. Joseph
    • 1
  • K. Schwartzman
    • 3
  • N. Kreiger
    • 4
  • A. Tenenhouse
    • 5
  • D. Goltzman
    • 2
    • 6
  • For the Canadian Multicentre Osteoporosis Study (CaMos)
  1. 1.Department of Epidemiology and BiostatisticsMcGill UniversityMontrealCanada
  2. 2.Division of Endocrinology, Department of MedicineMcGill UniversityMontrealCanada
  3. 3.Respiratory Division and Respiratory Epidemiology Unit, Department of MedicineMcGill UniversityMontrealCanada
  4. 4.Department of Public Health SciencesUniversity of TorontoTorontoCanada
  5. 5.Professor Emeritus, McGill UniversityMontrealCanada
  6. 6.Bone and Calcium Research LaboratoriesRoyal Victoria HospitalMontrealCanada

Personalised recommendations